Plaster for topical use containing heparin and diclofenac
Plaster for topical use having an analgesic activity and at the same time being able to re-absorb haematomas, comprising: a substrate layer; an adhesive layer in the form of a hydrogel matrix containing a pharmaceutically acceptable diclofenac salt, heparin or a heparinoid; a protective film which can be removed at the moment of use.
1. A therapeutic method for an analgesic and re-absorption treatment of hematomas which consists of a topical application of a bandage comprising: a) a substrate layer; b) an adhesive layer in the form of a polymeric hydrogel matrix comprising a pharmaceutically acceptable diclofenac salt and heparin or a heparinoid, at least one thickening agent, at least one wetting agent, at least one cross-linking agent, and c) a protective film which can be removed at the moment of use, wherein said hydrogel matrix further comprises a surfactant consisting of a polyoxyethylene sorbitan ester and a stabilizer consisting of sodium ethylenediamine tetraacetate.
2. The method according to claim 1 , characterized in that the diclofenac salt is in the form of a salt with an alicyclic amine of general formula
:in which m is 0 or 1.
3. The method according to claim 1 characterized in that the diclofenac salt is the salt of N-hydroxyethyl pyrrolidine.
4. The method according to claim 1 , characterized in that the concentration of the diclofenac salt is between 0.1 and 5 wt % with respect to the hydrogel matrix.
5. The method according to claim 4 , characterized in that the concentration of the diclofenac salt is between 0.3 and 3 wt % with respect to the hydrogel matrix.
6. The method according to claim 1 in which the concentration of heparin or heparinoid is between 0.05 and 1 wt % with respect to the hydrogel matrix.
7. The method according to claim 1 characterized in that the pH of the composition used for the preparation of the hydrogel matrix is between 7.2 and 9.
8. The method according claim 7 , characterized in that the pH is between 7.5 and 8.5.
9. The method according to claim 1 in which the concentration of polyoxyethylene sorbitan ester is 0.2 wt % with respect to the hydrogel matrix.
10. The method according to claim 1 , wherein the concentration of sodium ethylene diamine tetraacetate is 0.12% by weight with respect to the hydrogel matrix.
11. The method according to claim 1 , characterized in that the concentration of the diclofenac salt is between 0.1 and 5 wt % with respect to the hydrogel matrix.
12. The method according to claim 1 , characterized in that the concentration of the diclofenac salt is between 0.3 and 3 wt % with respect to the hydrogel matrix.
13. The method according to claim 2 in which the concentration of heparin or heparinoid is between 0.05 and 1 wt % with respect to the hydrogel matrix.
14. The method according to claim 2 characterized in that the pH of the composition used for the preparation of the hydrogel matrix is between 7.2 and 9.
15. The method according to claim 2 in which the concentration of polyoxyethylene sorbitan ester is 0.2 wt % with respect to the hydrogel matrix.